Celltrion Archives | Page 2 of 5 | Be Korea-savvy
Celltrion Inks Supply Agreement for COVID-19 Test Kit in U.S.

Celltrion Inks Supply Agreement for COVID-19 Test Kit in U.S.

SEOUL, Nov. 2 (Korea Bizwire) — South Korean biopharmaceutical giant Celltrion Inc. said Monday it has signed an agreement worth 210 billion won (US$185 million) to supply a diagnostic kit for the novel coronavirus in the United States. Under the agreement, Celltrion’s rapid antigen kit, Sampinute, will be distributed by Prime Healthcare Distributors in the [...]

Celltrion to Conduct Additional Phase 1 Trial for Coronavirus Treatment

Celltrion to Conduct Additional Phase 1 Trial for Coronavirus Treatment

SEOUL, Aug. 26 (Korea Bizwire) — Celltrion Inc., a leading pharmaceutical firm in South Korea, said Wednesday that it will conduct an additional phase one clinical trial of its coronavirus treatment on patients. Celltrion’s CT-P59 will be administered to nine COVID-19 patients with mild symptoms to evaluate the safety and efficacy of the antiviral antibody [...]

S. Korea Approves Phase 1 Trials for Celltrion’s COVID-19 Treatment Substance

S. Korea Approves Phase 1 Trials for Celltrion’s COVID-19 Treatment Substance

SEOUL, July 17 (Korea Bizwire) — South Korea approved phase one clinical trials for Celltrion Inc.’s coronavirus antibody treatment substance, the country’s drug safety agency said Friday. The move to test CT-P59 marks the first time that a locally made genetic recombination antibody treatment material has been given the green light to be used on [...]

Celltrion Eyes Exports of Virus Test Kits in July

Celltrion Eyes Exports of Virus Test Kits in July

SEOUL, June 16 (Korea Bizwire) — South Korean biopharmaceutical firm Celltrion Inc. said Tuesday that it will export two kinds of diagnostic kits for the novel coronavirus starting next month. A point-of-care antigen testing (POCT) kit, co-developed by local health care firm BBB, will first be commercialized in countries that lack diagnostic infrastructure, Celltrion said. [...]